Tempus AI, Inc. Class A TEM 深 沪
已收盘 03-27 16:00:00 美东时间
42.62
-2.910
-6.39%
华盛通- 最 高45.07
- 今 开44.945
- 成交量 570.60万股
- 最 低 42.19
- 昨 收 45.53
- 总市值 76.19亿
- 52周最高 104.32
- 市盈率 静 --
- 换手率 3.19%
- 52周最低 36.22
- 委 比 -57.46%
- 总股本 1.79亿
- 历史最高 104.32
- 量 比 1.29
- 振 幅 6.33%
- 历史最低 22.89
- 每 手 1
- 风险率 13.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cathie Wood Chooses Medical AI Over Mark Zuckerberg: Ark Loads Up On TEM Stock, Dumps Meta Shares
Cathie Wood's Ark Invest bought Tempus AI shares while trimming Meta, signaling a shift toward medical AI over big tech exposure.
03-26 10:37
Tempus AI Partners With Blood Cancer United Over Patient Registry For Pediatric Acute Myeloid Leukemia
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit
03-17 20:32
Chasing Emerging Markets Growth: T. Rowe Price Unveils New Active ETF
T. Rowe Price launches the Emerging Markets Equity Research ETF (TEMR), an actively managed fund targeting long-term growth across emerging markets stocks.
03-13 02:30
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
Why Tempus AI Stock Is Up Wednesday?
Tempus AI shares are trading higher Wednesday after Needham analyst Ryan MacDonald reiterated a Buy rating and maintained a $75 price target.
03-11 22:39
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
HC Wainwright & Co. Maintains Buy on Tempus AI, Raises Price Target to $95
HC Wainwright & Co. analyst Yi Chen maintains Tempus AI (NASDAQ:TEM) with a Buy and raises the price target from $89 to $95.
03-10 01:47
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
AI-Powered Tempus Inks New Multi-Year Merck Deal
Tempus AI expands its Merck deal as markets slide. Analysts stay bullish, but the stock trades near 52-week lows.
03-04 03:33
Benzinga Bulls And Bears: Rocket Lab, Kosmos Energy, Novo Nordisk — And Nvidia Fails To Boost Markets
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
02-28 19:42
